Lupin Limited
LUPIN · Pharma · NSE
₹2,309
Current Market Price
Fair Value (DCF)
₹2,681
Margin of Safety
+16.1%
Updated 9h ago
YieldIQ Score
37/100
Piotroski F-Score
6/9
Economic Moat
Moderate
Confidence
45%
ROE
19.0%
Debt/Equity
0.00
WACC
9.8%
Market Cap
₹1.06 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
21.2%
Return on capital employed
EV / EBITDA
17.2×
Enterprise multiple
Debt / EBITDA
0.9×
Leverage vs earnings
Interest Coverage
15.8×
EBIT covers interest
Current Ratio
1.87×
Short-term liquidity
Asset Turnover
0.84×
Revenue per ₹ of assets
Revenue CAGR (3Y)
—
3-year revenue growth
Revenue CAGR (5Y)
10.0%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹2,309
Bear case
₹1,588.67
MoS -45.3%
Base case
₹2,681.04
MoS +13.9%
Bull case
₹3,683.78
MoS +37.3%
Ratio Trends
LUPIN · last 8 annual periods
ROE
19.0%
ROCE
24.0%
Operating Margin
—
Debt / Equity
0.32×
PE
122.3×
EV / EBITDA
17.8×
Historical Financials
LUPIN · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹15.2K Cr | ₹16.4K Cr | ₹4430 Cr | ₹4961 Cr | ₹22.2K Cr | +10.0% |
| EBITDA | — | ₹394 Cr | ₹1837 Cr | ₹3898 Cr | ₹5455 Cr | +92.9% |
| EBIT | ₹1816 Cr | ₹-1230 Cr | ₹351 Cr | ₹569 Cr | — | -25.2% |
| PAT | ₹1228 Cr | ₹-1509 Cr | ₹242 Cr | ₹368 Cr | ₹3282 Cr | +27.9% |
| EPS (diluted) | ₹26.97 | ₹-33.65 | ₹5.16 | ₹7.86 | — | -26.5% |
| CFO | ₹1239 Cr | ₹1082 Cr | ₹1934 Cr | ₹3490 Cr | ₹3000 Cr | +24.7% |
| CapEx | — | — | — | — | ₹-1682 Cr | — |
| FCF | — | — | — | — | ₹1318 Cr | +0.0% |
| Total Assets | — | ₹21.8K Cr | ₹23.0K Cr | ₹24.0K Cr | ₹29.2K Cr | +7.6% |
| Total Debt | — | — | ₹4217 Cr | ₹2670 Cr | ₹5448 Cr | +6.6% |
| Shareholders' Equity | — | — | ₹12.5K Cr | ₹14.3K Cr | ₹17.3K Cr | +8.5% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
LUPIN vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| DRREDDY Dr. Reddy's Laboratories Limited | +73.3% | 63 | Undervalued | 16.8% | 16.8× |
| CIPLA Cipla Limited | +43.1% | 66 | Data Limited | 16.9% | 22.1× |
| ZYDUSLIFE Zydus Lifesciences Limited | +47.7% | 45 | Data Limited | 17.2% | — |
| MANKIND Mankind Pharma Limited | -38.3% | 40 | Overvalued | 13.7% | — |
| TORNTPHARM Torrent Pharmaceuticals Limited | -48.8% | 28 | Overvalued | 25.2% | — |
Click a ticker to view its fair-value analysis.
Dividend History
10 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹34.50/sh
Last payout
2025-07-25
₹12.00
Peak payout
₹12.00
Trailing yield
0.52%
Amounts parsed from NSE subject lines; percent-of-face-value declarations are not converted and shown as missing.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Lupin Limited (LUPIN.NS) trades at 2309.00 vs a model fair value of 2681.04, a gap of 16.1%. Piotroski F-score: 6/9. Moat label: Moderate...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of LUPIN →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for LUPIN →
Compare
Head-to-head with peers
Compare LUPIN side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse LUPINNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.